spacer
home > epc > winter 2018 > marking safety
PUBLICATIONS
European Pharmaceutical Contractor

Marking Safety

“Sepsis is the most preventable cause of death” (1), and every hour it is not diagnosed will increase the probability of killing the patient by 7%; thus, recognising the early signs and symptoms is crucial. Severe sepsis is the leading cause of death in the noncoronary intensive care unit, with mortality rates between 30-50%.

According to Dr Adam Linder, “approximately one in five patients with sepsis who are admitted to hospital are at risk of developing severe sepsis within the first 24 hours” (2). Furthermore, it is also the biggest killer of children under five worldwide. Konrad Reinhart notes that 6 million babies from third-world countries and 10,000 of mothers die from the condition every year (1).

As sepsis often impacts the elderly (usually when they have some other condition), it is perhaps less talked about, but it also affects children. With such susceptible groups as these, anything that raises awareness among medical staff of the signs, symptoms, and dangers can only be a good thing.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Professor Christene Leiper attended Sydney University, RMIT Melbourne, and Bond University in Australia and achieved a Professor of Medicine and Life Sciences at Bond University Queensland in 2006. She also undertook research at Edinburgh University, Scotland, as part of her PhD. Christene has been a Principal Investigator for clinical trials, which enables her to operate across many disciplinary boundaries within clinical research in a coherent and productive manner. In 2007, she was appointed Director of Research at a Scottish CRO, which in turn, led her to start her own CRO, Onorach, in 2009.
spacer
Professor Christene Leiper
spacer
spacer
Print this page
Send to a friend
Privacy statement

White Papers

Mauritius Island – An Emerging Centre for R&D in Biotechnology and the Life Sciences

CIDP (Centre International de Développement Pharmaceutique)

Mauritius, the tropical island situated in the Indian Ocean and known worldwide for its beautiful beaches, is also internationally recognised for its rule of law, and political and social stability. Over the past few years, the economy has been successfully transitioned from a monocrop to a diversified innovation-driven and knowledge-based economy, resting on agribusiness, export-oriented manufacturing, tourism, financial services, property development and real estate, ICT-BPO, the seafood industry, a free port, logistics and a nascent ocean economy. Emerging sectors such as healthcare and life sciences are presenting some niche areas for the taking, and the enabling environment is being put in place to make it happen - especially in the light of sustained growth within pharmaceutical, medical device, and clinical research. Important international players are already in operation locally as the country has established the appropriate legal and regulatory frameworks based on international norms, for the development of a strong biomedical research sector.
More info >>

 
Industry Events

Clinical Trial Supply Europe 2019

13-14 March 2019, Milan, Italy

Following on from our largest and most engaging meeting to date, Clinical Trial Supply Europe will be returning to Milan for its 20th year in 2019! The 19th annual edition welcomed pharmaceutical companies across Europe who got together to share knowledge and issues regarding clinical trial supplies, both with regards to operational and technological challenges. Over the two days, delegates discussed issues which affected their business in our dedicated operational and technological streams.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement